JP5840609B2 - イメージングに用いるパーフルオロ化合物 - Google Patents

イメージングに用いるパーフルオロ化合物 Download PDF

Info

Publication number
JP5840609B2
JP5840609B2 JP2012522296A JP2012522296A JP5840609B2 JP 5840609 B2 JP5840609 B2 JP 5840609B2 JP 2012522296 A JP2012522296 A JP 2012522296A JP 2012522296 A JP2012522296 A JP 2012522296A JP 5840609 B2 JP5840609 B2 JP 5840609B2
Authority
JP
Japan
Prior art keywords
contrast agent
fmri
imaging
combination
perfluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012522296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500959A5 (enExample
JP2013500959A (ja
Inventor
イルディリム，ムハメド
グリュル，ホルガー
マティアス ヨハネス ニコラース ラメリクス，ルドルフ
マティアス ヨハネス ニコラース ラメリクス，ルドルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Publication of JP2013500959A publication Critical patent/JP2013500959A/ja
Publication of JP2013500959A5 publication Critical patent/JP2013500959A5/ja
Application granted granted Critical
Publication of JP5840609B2 publication Critical patent/JP5840609B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012522296A 2009-07-31 2010-07-21 イメージングに用いるパーフルオロ化合物 Expired - Fee Related JP5840609B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166955.6 2009-07-31
EP09166955 2009-07-31
PCT/IB2010/053321 WO2011013038A2 (en) 2009-07-31 2010-07-21 Perfluoro compounds for use in imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015221770A Division JP2016029098A (ja) 2009-07-31 2015-11-12 イメージングに用いるパーフルオロ化合物

Publications (3)

Publication Number Publication Date
JP2013500959A JP2013500959A (ja) 2013-01-10
JP2013500959A5 JP2013500959A5 (enExample) 2014-12-18
JP5840609B2 true JP5840609B2 (ja) 2016-01-06

Family

ID=43304070

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012522296A Expired - Fee Related JP5840609B2 (ja) 2009-07-31 2010-07-21 イメージングに用いるパーフルオロ化合物
JP2015221770A Pending JP2016029098A (ja) 2009-07-31 2015-11-12 イメージングに用いるパーフルオロ化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015221770A Pending JP2016029098A (ja) 2009-07-31 2015-11-12 イメージングに用いるパーフルオロ化合物

Country Status (5)

Country Link
US (1) US20120128589A1 (enExample)
EP (1) EP2459235B1 (enExample)
JP (2) JP5840609B2 (enExample)
CN (1) CN102497888B (enExample)
WO (1) WO2011013038A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101906574B1 (ko) * 2013-01-15 2018-10-10 주식회사 엘지생활건강 발수성을 가지는 칫솔모 및 이를 포함하는 칫솔
CN118859065A (zh) * 2024-07-01 2024-10-29 中国科学院精密测量科学与技术创新研究院 一种利用凝血级联放大提升19f mri肿瘤信噪比的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4453028A (en) * 1982-03-29 1984-06-05 Lagow Richard J Perfluorinated compounds with cyclohexyl groups
US5236694A (en) 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5571498A (en) 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
US6167887B1 (en) * 1997-11-21 2001-01-02 Synthetic Blood International, Inc. Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6574497B1 (en) * 2000-12-22 2003-06-03 Advanced Cardiovascular Systems, Inc. MRI medical device markers utilizing fluorine-19
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
US8777889B2 (en) * 2004-06-15 2014-07-15 Ceramatec, Inc. Apparatus and method for administering a therapeutic agent into tissue
JP2008517997A (ja) 2004-10-29 2008-05-29 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 超音波撮像における造影剤として使用するための粒子の分散調合
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
WO2008075276A1 (en) * 2006-12-19 2008-06-26 Koninklijke Philips Electronics N.V. Method and system to convert 2d video into 3d video
CN101636663B (zh) * 2007-03-19 2013-11-20 皇家飞利浦电子股份有限公司 磁共振设备和方法
EP1985312A1 (en) 2007-04-25 2008-10-29 Koninklijke Philips Electronics N.V. T1 reduction in 19F magnetic resonance imaging (MRI)
KR101005561B1 (ko) * 2008-06-21 2011-01-05 한국생명공학연구원 광학특성 나노입자 및 퍼플루오로카본으로 구성된 나노에멀젼을 이용한 다중모드 조영 방법
WO2010121082A2 (en) * 2009-04-15 2010-10-21 Oxygen Biotherapeutics, Inc. Emulsions of perfluorocarbons

Also Published As

Publication number Publication date
US20120128589A1 (en) 2012-05-24
WO2011013038A3 (en) 2011-05-05
CN102497888A (zh) 2012-06-13
JP2016029098A (ja) 2016-03-03
EP2459235A2 (en) 2012-06-06
CN102497888B (zh) 2014-10-29
JP2013500959A (ja) 2013-01-10
EP2459235B1 (en) 2014-04-23
WO2011013038A2 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
Bort et al. EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles
Hsu et al. Nanomaterial-based contrast agents
Serkova et al. Preclinical applications of multi-platform imaging in animal models of cancer
Arms et al. Advantages and limitations of current techniques for analyzing the biodistribution of nanoparticles
Park et al. Towards clinically translatable in vivo nanodiagnostics
Ehlerding et al. Big potential from small agents: nanoparticles for imaging-based companion diagnostics
Li et al. Multimodality imaging in nanomedicine and nanotheranostics
Lanza et al. 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles
Mirabello et al. Metallic nanoparticles as synthetic building blocks for cancer diagnostics: from materials design to molecular imaging applications
Xue et al. Design of ProCAs (Protein‐Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers
Misri et al. Nanoprobes for hybrid SPECT/MR molecular imaging
Wu et al. Nanoparticle‐based imaging of inflammatory bowel disease
Gonawala et al. Application of dendrimer-based nanoparticles in glioma imaging
Opacic et al. Status and trends in the development of clinical diagnostic agents
Shaghaghi et al. Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET
Calle et al. Advanced contrast agents for multimodal biomedical imaging based on nanotechnology
Liu et al. Nanoprobes for PET/MR imaging
JP2016029098A (ja) イメージングに用いるパーフルオロ化合物
JP2020019763A (ja) マルチモーダルｐｅｔ／ｍｒｉ造影剤およびその合成方法
Wang et al. Exponential growth of publications on carbon nanodots by Chinese authors
JP2013500959A5 (enExample)
Chandra et al. Role of contrast in MR imaging
Liu et al. Translational nanodiagnostics for in vivo cancer detection
Kang Preliminary pre-clinical results and overview on PET/MRI/fluorescent molecular imaging
Geraldes Imaging Applications of Inorganic Nanomaterials

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140729

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151111

R150 Certificate of patent or registration of utility model

Ref document number: 5840609

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees